AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.24 |
Market Cap | 71.32M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.99 |
PE Ratio (ttm) | -0.83 |
Forward PE | n/a |
Analyst | Hold |
Ask | 2.61 |
Volume | 605,787 |
Avg. Volume (20D) | 800,431 |
Open | 2.51 |
Previous Close | 2.50 |
Day's Range | 2.43 - 2.51 |
52-Week Range | 1.25 - 32.41 |
Beta | undefined |
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered...
Analyst Forecast
According to 7 analyst ratings, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $2, which is a decrease of -19.03% from the latest price.